PL Capital believes the company is well positioned to benefit from increasing pharmaceutical outsourcing, a deep commercial pipeline and capacity expansion
Already jumped 55% in 2026, PL Capital sees more returns in Sai Lifesciences shares | Check target, upside
Published ·

Keep reading

